Vault-13

PSYENCE BIOMEDICAL LTD

COM NEW · CUSIP 74449F209

0 institutional holders -1 vs Q2 2025
—reported value*
0 new 0 added 0 reduced 1 sold out net sold ≈ $462.0k (-275.0k shares)

* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.

Trends to Q3 2025

Institutional holders

Managers reporting a position, each quarter

051015Q4 24: 12Q1 25: 9Q2 25: 1Q3 25: 00Q4 24Q1 25Q2 25Q3 25
Numbers
QuarterHolders
Q4 202412
Q1 20259
Q2 20251
Q3 20250

Buyers vs sellers

Managers adding to or starting a position, vs cutting or selling out

Bought or addedCut or sold out
10010Q1 25: 8 bought or addedQ1 25: 7 cut or sold outQ1 25Q2 25: 1 bought or addedQ2 25: 9 cut or sold outQ2 25Q3 25: 0 bought or addedQ3 25: 1 cut or sold outQ3 25
Numbers
QuarterBought or addedCut or sold out
Q1 202587
Q2 202519
Q3 202501

Biggest buyers

None

Biggest sellers

Parallel Advisors, LLC Sold out -275,000-275.0k

Major shareholders (over 5%)

Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.

HolderStakeChangeShares Last filed
Psyence Group Inc. 13D · may seek influence filed 2025-03-25
Stated purposeThe information set forth in Item 3 is hereby incorporated by reference in its entirety. Except for the foregoing, the Reporting Person has no plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) and (c) through (j) of Item 4 of Schedule 13D. Full filing
15.0% 678.7k 2025-03-25

Holders, Q3 2025

#ManagerLocationShares Value% of their portfolioChangeShares change